%0 Journal Article
%T Whither CAR T? will the FDA being under the hood and the availability of bispecifics make these therapies less attractive?
%A Chao S
%A Tse J
%A VanGalder A
%A Wong G
%A Wonsettler T
%A Hertler A
%J Am J Manag Care
%V 30
%N 7
%D 2024 Jun
%M 38899962
%F 3.247
%R 10.37765/ajmc.2024.89576